The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
复制标题
DOI:
10.1016/j.vaccine.2021.08.102
复制
发表时间:
2021-10-08
期刊:
影响因子:
5.5
通讯作者:
Chanmugam A
中科院分区:
文献类型:
--
作者:
Raina MacIntyre C;Costantino V;Chanmugam A
Face masks were mandated in New York during the first wave in 2020, and in 2021 the first vaccine programs have commenced. We aimed to examine the impact of face mask and other NPIs use with a gradual roll out of vaccines in NYC on the epidemic trajectory. A SEIR mathematical model of SARS-CoV-2 transmission was developed for New York City (NYC), which accounted for decreased mobility for lockdown, testing and tracing. Varied mask’s usage and efficacy were tested, along with a gradual increase in vaccine uptake over five months. The model has been calibrated using notification data in NYC from March first to June 29. Masks and other NPIs result in immediate impact on the epidemic, while vaccination has a delayed impact, especially when implemented over a long period of time. A pre-emptive, early mandate for masks is more effective than late mask use, but even late mask mandates will reduce cases and deaths by over 20%. The epidemic curve is suppressed by at least 50% of people wearing a mask from the start of the outbreak but surges when mask wearing drops to 30% or less. With a slow roll out of vaccines over five months at uptake levels of 20–70%, NPIs use will still be needed and has a greater impact on epidemic control. When vaccine roll out is slow or partial in cities experiencing local transmission of COVID-19, masks and other NPIs will be necessary to mitigate transmission until vaccine coverage is high and complete. Vaccine alone cannot rapidly control an epidemic because of the time lag to two-dose immunity. Even after high coverage, the ongoing need for NPIs is unknown and will depend on long-term duration of vaccine efficacy, the use of boosters and optimized dosage scheduling and variants of concern.
登录
查看更多内容
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
DOI:
10.3138/jammi-2020-0030
发表时间:
2020-12-01
期刊:
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada
影响因子:
--
作者:
Byambasuren, Oyungerel;Cardona, Magnolia;Glasziou, Paul
通讯作者:
Glasziou, Paul
DOI:
10.1056/nejmoa2035389
发表时间:
2021-02-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者:
COVE Study Group
影响因子:
82.9
作者:
He, Xi;Lau, Eric H. Y.;Leung, Gabriel M.
通讯作者:
Leung, Gabriel M.
影响因子:
56.3
作者:
Badr, Hamada S.;Du, Hongru;Gardner, Lauren M.
通讯作者:
Gardner, Lauren M.